Well-differentiated thyroid carcinoma: The role of post-operative radioactive iodine administration

Authors

  • Supriya S Patel MD,

    1. Division of Breast/Soft Tissue and Endocrine Surgery, University of Southern California Keck School of Medicine, Los Angeles, California
    Search for more papers by this author
  • Melanie Goldfarb MD

    Corresponding author
    1. Division of Breast/Soft Tissue and Endocrine Surgery, University of Southern California Keck School of Medicine, Los Angeles, California
    • Assistant Professor of Surgery, Division of Breast/Soft Tissue and Endocrine Surgery, Department of Surgery, University of Southern California Keck School of Medicine, 1510 San Pablo St, Suite 412K Los Angeles, CA 90033. Fax: 323-865-3539.===

    Search for more papers by this author

Abstract

Post-operative management of differentiated thyroid cancer (DTC) often involves administration of radioactive iodine (RAI) for remnant ablation or adjuvant therapy. However, given the favorable prognosis associated with DTC, the risk versus benefit ratio of RAI remains unclear. RAI is associated with substantial, albeit rare side effects, including a possible increased risk of secondary malignancy and altered fertility, which must be balanced against the magnitude of benefit for decreasing recurrence and improving survival. J. Surg. Oncol. 2013;107:665–672. © 2012 Wiley Periodicals, Inc.

Ancillary